EP2744475A2 - Formulation cosmétique contenant n-acyl-phytosphingosine - Google Patents

Formulation cosmétique contenant n-acyl-phytosphingosine

Info

Publication number
EP2744475A2
EP2744475A2 EP12775260.8A EP12775260A EP2744475A2 EP 2744475 A2 EP2744475 A2 EP 2744475A2 EP 12775260 A EP12775260 A EP 12775260A EP 2744475 A2 EP2744475 A2 EP 2744475A2
Authority
EP
European Patent Office
Prior art keywords
phytosphingosine
formulation
skin
hexanoyl
cosmetic formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12775260.8A
Other languages
German (de)
English (en)
Inventor
Mike Farwick
Matthias MENTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Industries AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Industries AG filed Critical Evonik Industries AG
Publication of EP2744475A2 publication Critical patent/EP2744475A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/49—Solubiliser, Solubilising system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins

Definitions

  • N-acyl-phytosphingosine can be produced from the combination of N-acyl-phytosphingosine and 1, 2-pentanediol cosmetic formulations, which are particularly well suited for use on the skin.
  • the N-acyl phytosphingosine is N-hexanoyl-phytosphingosine.
  • a particularly good cosmetic effect on the skin could be achieved.
  • the formulation comprises no further ceramides in addition to the N-acyl-phytosphingosine. Surprisingly, it was found that very good cosmetic effects could already be achieved with N-acyl-phytosphingosine as the only ceramide.
  • the N-acyl phytosphingosine is included in the formulation at a level of from 0.02% to 2% by weight based on the total formulation.
  • the N-acyl-phytosphingosine is included in the formulation in a concentration of 0.1% to 1% by mass, based on the total formulation. For these mass concentrations could be particularly good cosmetic
  • Emollients, emulsifiers and surfactants, thickeners / viscosity regulators / stabilizers, UV light protection filters, antioxidants, hydrotropes (or polyols), solids and fillers, for example, are also included as auxiliary substances contained in the cosmetic formulation.
  • Film formers pearlescing additives, deodorant and antiperspirant active ingredients, insect repellents, self-tanning agents, preservatives, conditioners, perfumes, dyes, biogenic agents, care additives, superfatting agents and other solvents.
  • herbal extracts are chestnut extract, chamomile extract, rosemary extract, black and red currant extract, birch extract, rosehip extract, algae extracts, green tea extract, aloe extract, ginseng extract, ginko extract, grapefruit extract, calendula extract, cucumber extract, Camphor, Thymus Extract, Mangosteen Extract, Cystus Extract, Terminalia Arjuna extract, oat extract, oregano extract, raspberry extract, strawberry extract, etc.
  • the so-called barrier lipids can be counted, for example, ceramides, phytosphingosine and derivatives, sphingosine and derivatives, sphinganine and derivatives, pseudoceramides, phospholipids , Lysophospholipids, cholesterol and derivatives, cholesteryl esters, free fatty acids, lanolin and derivatives, squalane, squalene and related substances.
  • the biogenic active substances are also anti-acne such as benzyl peroxide, phytosphingosine and derivatives, niacinamide hydroxybenzoate, nicotinaldehyde, retinoic acid and derivatives, salicylic acid and derivatives, citronellic acid etc.
  • anti-acne such as benzyl peroxide, phytosphingosine and derivatives, niacinamide hydroxybenzoate, nicotinaldehyde, retinoic acid and derivatives, salicylic acid and derivatives, citronellic acid etc.
  • the cosmetic formulation comprises
  • Glycolipids medium chain triglycerides, branched chain fatty alcohols such as octyldodecanol, taurine, phospholipids, 1,2-pentylene glycol and C8 / C10 glycerol partial esters
  • the cosmetic formulation C12-15 Alkyl Benzoate, particularly TEGOSOFT ® TN comprises. Particularly good values could be achieved with this additional excipient.
  • the cosmetic formulation comprises PPG-13 myristyl ether, in particular TEGOSOFT ® APM. Particularly good values could be achieved with this additional excipient.
  • the cosmetic formulation octyl dodecanol, in particular TEGOSOFT ® G20 comprises. Particularly good values could be achieved with this additional excipient.
  • Claimed is the use of a previously described formulation for application to the skin.
  • the excipient for example, be a solvent and thus, for example, 1, 2-pentanediol.
  • 1, 2-pentanediol in a preferred variant of the use of the excipient is 1, 2-pentanediol.
  • Embodiments should be limited.
  • Example 1 Investigation of the influence of N-hexanoyl-phytosphingosine on the
  • the cells were further incubated with this medium for 12 days, with a media change every three days. Subsequently, the medium was removed from the cells and replaced with fresh medium with N-hexanoyl-phytosphingosine. Methanol was used as the vehicle, the final concentration of the vehicle in the medium being 0.05% (v / v). Final concentration of N-hexanoyl-phytosphingosine in Medium was 2.5 ⁇ .
  • the cultivation was carried out without active ingredient, only with medium (vehicle). All cultivations were done twice (with cells 2
  • Stearin (Stearic acid (and) 0,50 0,50 0,50 0,50 0,50 0,50 palmitic acid)
  • Amount of active ingredient which must be introduced into the formulation can be reduced at a high bioavailability.
  • Example 5 Reduction of Skin Tear on the Upper Arm by N-Hexanoyl Phytosphingosine
  • the reduction of skin slack in the upper arm, quantifiable by the parameter of echogenicity of the skin, by topical application of N-hexanoyl-phytosphingosine in formulation was demonstrated in a human study.
  • the panel included healthy female subjects of Caucasian origin, up to seventy years of age, in their postmenopausal stage.
  • the echogenicity of the skin on the upper arms of the subjects was at most 60% (DermaScan ® C, B-scan mode).
  • the formulations were applied on the upper arms.
  • Vehicle formulation (vehicle) and formulation with different concentrations of N-hexanoyl-phytosphingosine (N-hexanoyl-phytosphingosine) was applied by 16 subjects each.
  • N-hexanoyl-phytosphingosine N-hexanoyl-phytosphingosine
  • Stearin Stearin (Stearic acid (and) palmitic 0.50 0.50 0.50 0.50
  • Glycerol (glycerin) 2.50 2.50 2.50
  • the measurements took place in a temperature and humidity controlled room (24 + 2 ° C, 50 ⁇ 10 relative humidity). Subjects were asked not to apply any product for up to twelve hours prior to measurement and to stop their arms from being washed for three hours prior to measurement.
  • the sagging was measured by measuring the echogenicity of the skin by means of ultrasonic scanners Dermascan ® C.
  • the echogenicity was in B-scan mode
  • Figure 5 shows the increase in skin density on the upper arm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une formulation cosmétique et son utilisation.
EP12775260.8A 2011-10-31 2012-10-23 Formulation cosmétique contenant n-acyl-phytosphingosine Withdrawn EP2744475A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011085497A DE102011085497A1 (de) 2011-10-31 2011-10-31 Kosmetische Formulierung
PCT/EP2012/070909 WO2013064388A2 (fr) 2011-10-31 2012-10-23 Formulation cosmétique

Publications (1)

Publication Number Publication Date
EP2744475A2 true EP2744475A2 (fr) 2014-06-25

Family

ID=47046624

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12775260.8A Withdrawn EP2744475A2 (fr) 2011-10-31 2012-10-23 Formulation cosmétique contenant n-acyl-phytosphingosine

Country Status (8)

Country Link
US (1) US20140309309A1 (fr)
EP (1) EP2744475A2 (fr)
JP (1) JP2014532675A (fr)
KR (1) KR20140096042A (fr)
CN (1) CN103917217A (fr)
BR (1) BR112014010349A2 (fr)
DE (1) DE102011085497A1 (fr)
WO (1) WO2013064388A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3021540B1 (fr) * 2014-06-03 2016-06-03 Caster Compositions de soins de la peau
KR101944716B1 (ko) * 2016-07-06 2019-02-01 주식회사 피토스 N-아세틸 피토스핑고신-1-포스페이트를 함유하는 주름개선 및 노화방지를 위한 화장품용 조성물
JP2020514739A (ja) * 2017-03-06 2020-05-21 ハプルサイエンス・インコーポレイテッド Ｈａｐｌｎ１を利用した皮膚老化の測定用または予防用または改善用の組成物
JP7222001B2 (ja) * 2021-01-22 2023-02-14 ハプルサイエンス・インコーポレイテッド Ｈａｐｌｎ１を利用した皮膚老化の測定用または予防用または改善用の組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308103D0 (en) * 1993-04-20 1993-06-02 Unilever Plc Cosmetic composition
JPH101414A (ja) * 1996-06-12 1998-01-06 Kanebo Ltd 皮膚化粧料
FR2767056A1 (fr) * 1997-08-07 1999-02-12 Oreal Utilisation d'un 2-amino-alcane polyol en tant qu'agent destine a traiter les signes du vieillissement cutane
JP4255621B2 (ja) 1998-05-14 2009-04-15 コスモフェルム ベスローテン フェンノートシャップ アミノアルコールのアシル化方法
JP2000264826A (ja) * 1999-03-16 2000-09-26 Ryuhodo Seiyaku Kk 液晶組成物およびそれが配合されてなる皮膚化粧料
JP3730102B2 (ja) * 2000-09-14 2005-12-21 ポーラ化成工業株式会社 透過促進用の皮膚外用剤
JP2003176210A (ja) * 2001-12-12 2003-06-24 Nonogawa Shoji Kk 乳化型化粧料
JP2005535717A (ja) * 2002-08-14 2005-11-24 キム，テユン フィトスフィンゴシン誘導体を含むアポトーシス誘導用組成物
JP2008044857A (ja) * 2006-08-11 2008-02-28 Toyobo Co Ltd 肌荒れ改善剤
RU2499607C2 (ru) * 2006-09-19 2013-11-27 Басф Се Косметические препараты на основе молекулярно впечатанных полимеров
CA2665552C (fr) 2006-10-13 2013-02-19 Evonik Goldschmidt Gmbh Composition de traitement cutane
JPWO2008053960A1 (ja) * 2006-11-02 2010-02-25 メルシャン株式会社 セラミド合成促進剤、化粧料、皮膚外用剤、老化防止方法およびしわ改善方法
WO2009149227A1 (fr) * 2008-06-06 2009-12-10 Lubrizol Advanced Materials, Inc. Composés d’ester pour utilisation dans des produits de soins personnels
DE102010002609A1 (de) * 2010-03-05 2011-09-08 Evonik Goldschmidt Gmbh Partialester eines Polyglycerins mit mindestens einer Carbonsäure und einer polyfunktionalen Carbonsäure, ihre Herstellung und Verwendung
DE102010029499A1 (de) 2010-05-31 2011-12-01 Evonik Goldschmidt Gmbh Polyolpartialester zur Anwendung in Kosmetik

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2013064388A2 *

Also Published As

Publication number Publication date
KR20140096042A (ko) 2014-08-04
WO2013064388A3 (fr) 2013-07-11
WO2013064388A2 (fr) 2013-05-10
DE102011085497A1 (de) 2013-05-02
CN103917217A (zh) 2014-07-09
BR112014010349A2 (pt) 2017-04-18
US20140309309A1 (en) 2014-10-16
JP2014532675A (ja) 2014-12-08

Similar Documents

Publication Publication Date Title
RU2613121C2 (ru) Косметические композиции
US9833642B2 (en) Skin care formulations
CN110742842B (zh) 一种延缓皮肤老化的精华组合物及其制备方法
KR102099993B1 (ko) 피부 케어 제형물
KR102092977B1 (ko) 피부톤 향상을 위한 식물 추출물의 조합물
EA025223B1 (ru) Состав для местного ухода за кожей и способ восстановления целостности дермально-эпидермального соединения тканей кожи
JP5779170B2 (ja) クエン酸カルシウムおよびｎ−アシル化アミノアルコール誘導体を含んでなる乾燥皮膚および皮膚老化の兆候を防ぐための化粧品組成物
US20070048243A1 (en) Anti-aging composition containing criste marine and padina pavonica extracts
WO2013064388A2 (fr) Formulation cosmétique
KR20150135433A (ko) 폴리고눔 비스토르타 추출물의 미용 또는 피부과 용도
EP2356980A2 (fr) Utilisation de dihydromyricétine pour les peaux matures
US9687431B2 (en) Use of isoleucine N-hexadecanoyl as a “volumizing” and/or “plumping” agent for human skin
EP2863874A2 (fr) Préparation cosmétique et dermatologique contenant une ou plusieurs substances modulant le gène / la protéine pour le récepteur endo180
US20030211183A1 (en) Skin-improving agent
KR101418979B1 (ko) 콜라겐 형성 촉진용 조성물 및 그를 이용한 화장품
FR2767690A1 (fr) Utilisations d'extraits de la plante rhoeo discolor dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
KR20170035658A (ko) 크립토클로로겐산을 유효성분으로 포함하는 피부 개선용 조성물
DE102011085493A1 (de) Arjunolsäure zur Erhöhung der Sebumproduktion
EP2863873B1 (fr) Préparation cosmétique et dermatologique contenant une ou plusieurs substances modulant le gène / la protéine pour le récepteur endo180
WO2020163942A1 (fr) Compositions topiques à forte concentration de vitamine c et leur procédé de fabrication
KR20220046360A (ko) 라우로일 메틸글루카마이드 라우레이트(lauroyl methylglucamide laurate)를 유효성분으로 함유하는 화장료 조성물
KR20170035659A (ko) 페리빈을 유효성분으로 포함하는 피부 개선용 조성물
EP2589374A2 (fr) Utilisation d'extrait d'écorce de magnolia pour améliorer l'aspect de la peau ou lutter contre la cellulite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140320

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVONIK DEGUSSA GMBH

17Q First examination report despatched

Effective date: 20160720

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170627